Humana faces significant earnings headwinds due to CMS reforms, star rating downgrades, and potential Medicaid clawbacks.

Despite these developments, Humana's stock performance remained flat over the past week. During the same period, broader markets saw gains, bolstered by strong earnings from major tech companies.

Furthermore, Humana continues to face pressure from rising medical costs, and its benefits expense ratio increased by 270 bps y-o-y to 89%, weighing on its stock performance. Our detailed analysis ...

The company's recent financial performance has been mixed. While Humana has maintained a solid ... HUM appears on our undervalued or overvalued stock lists. These tools provide a clearer picture ...

and buyers emerged Humana Inc.'s stock was up 2% Friday after three straight sessions of declines, but investors paying attention to the performance of its bonds on Thursday may have had something ...

Humana (HUM) stock is plunging in Wednesday's session ... Sign up "The decline in Stars performance for 2025 will impact Humana's quality bonus payments in 2026," Humana said in the filing.

Sarah James, a stock analyst with Cantor Fitzgerald ... The lower rating won’t affect Humana’s performance until 2026, but the company said it was “disappointed with its performance and ...

Shares of Humana Inc. were suffering another beating ... insurer’s large Medicare Advantage plans because it missed some performance measures. Based on preliminary 2025 data from the Centers ...